Compare FMC Corp (FMC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Sana Biotechnology Inc — how do they compare? FMC Corp trades at $10.18 (market cap $1.30B), while Sana Biotechnology Inc trades at $3.76 (market cap $1.13B). The key difference: FMC Corp is the larger of the two by market cap, and FMC Corp pays a 3.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FMC | SANA | |
|---|---|---|
Market Cap | $1.30B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $5.92 |
52-Week Low | $10.01 | $2.68 |
Enterprise Value | $5.11B | $1.05B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.17, down 2.82% today, amid bearish technical signals and weak fundamentals. Recent Q2 2026 earnings beat estimates but revenue missed, with full-year guidance lowered. The company faces significant profitability challenges, with a net income margin of -84.83% and negative ROE/ROA. Positive developments include a $400 million minority investment from Tessenderlo Group and ongoing debt reduction efforts.
The outlook remains cautious due to persistent earnings pressure and high debt levels, though asset sales and external funding provide liquidity support. Analyst consensus is mixed with a $11.60 price target, suggesting modest upside potential if operational improvements materialize. Key risks include volatile cash flows, competitive pressures, and macroeconomic headwinds affecting agricultural demand.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
